3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Anus Neoplasms
1
Interventions
trastuzumab biosimilar HLX02
2
ribociclib
2
pertuzumab
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Paclitaxel
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Docetaxel
2
2C4 antibody
2
tucatinib
1
exemestane
1
durvalumab
1
Surgical Procedures, Operative
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiation
1
Mastectomy, Segmental
1
Mastectomy
1
Letrozole
1
Immunoglobulin G
1
High-Energy Shock Waves
1
Genetic Testing
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Anatomic Stage II Breast Cancer AJCC v8
×
bintrafusp alfa protein, human
×
1 year
×
Clear all
No trials found.